According to a press release, researchers from Tel Aviv University have made a groundbreaking discovery in the fight against brain cancer by preventing the spread of glioblastoma. Glioblastoma is an aggressive form of cancer that can occur in the brain or spinal cord. by detecting a failure in the brain’s immune system that can be used against deadly cancer. The failure in question stems from a protein called P-Selectin (SELP), which researchers have used to restore the normal activity of the brain, which blocks the spread of cancer. Ronit Satchi-Fainaro of the Sackler Faculty of Tel Aviv University led the international research team. Researchers also compare healthy brain tissues with other tissues infected with glioblastoma. “We investigated the interactions between the immune cells in the brain and the glioblastoma cells in tumors that were recently removed from patients’ brains,” Fainaro said. Researchers have investigated which proteins are secreted when the immune cells of microglia (the cells of the immune system) meet the glioblastoma cells, as cells are able to communicate with each other through proteins. Their studies led to the SELP protein, which appears to disrupt brain immune system functions and strengthen glioblastoma tumors. Fainaro believes the study may have therapeutic implications, as the possibility exists that SELP could be used to treat sickle cell-related pain.
cnxps.cmd.push (function () {cnxps ({playerId: ’36af7c51-0caf-4741-9824-2c941fc6c17b’}). deliver (‘4c4d856e0e6f4e3d808bbc1715e132f6’);});
if (window.location.pathname.indexOf (“656089”)! = -1) {console.log (“hedva connatix”); document.getElementsByClassName (“divConnatix”)[0].style.display = “none”;}